Image of Bluegrass Allergy Care in Lexington, United States.

Other

EVO756 for Chronic Urticaria

Lexington, KY

Phase 2

Waitlist Available

Research Sponsored by Evommune, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Summary

This trial will test how well and how safe EVO756 is for adults with moderate to severe chronic spontaneous urticaria.

See full description

Who is the study for?

Adults with moderate to severe chronic spontaneous urticaria (CSU) who haven't responded well to antihistamines can join. They must have a Urticaria Activity Score of 16 or more and been diagnosed for at least 3 months. Participants should not have other diseases causing similar symptoms, significant health issues unrelated to CSU, or be on certain medications.Check my eligibility

What is being tested?

The trial is testing how effective and safe different doses of EVO756 are compared to a placebo in adults with CSU. It's randomized, meaning people will be put into the EVO756 or placebo group by chance.See study design

What are the potential side effects?

Possible side effects from EVO756 aren't detailed here but may include reactions typical for new treatments in patients with chronic urticaria such as worsening of skin conditions, allergic responses, or other drug-related adverse events.